Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

[1] Parvaneh N(2013)Primary immunodeficiencies: a rapidly evolving story J Allergy Clin Immunol 131 314-323

[2] Casanova JL(2015)Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015 J Clin Immunol 35 696-726

[3] Notarangelo LD(2010)Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G South Med J 103 856-863

[4] Conley ME(1973)Primary immunodeficiency diseases and cancer: the immunodeficiency-cancer registry Int J Cancer 12 333-347

[5] Picard C(2008)Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency—lessons learned from monogenic disorders in mice and men Curr Opin Immunol 20 646-654

[6] Al-Herz W(2011)Key aspects for successful immunoglobulin therapy of primary immunodeficiencies Clin Exp Immunol 164 16-19

[7] Bousfiha A(2010)Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology Clin Immunol 135 255-263

[8] Casanova JL(2009)Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies J Clin Immunol 29 137-144

[9] Chatila T(2006)Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia Vox Sang 90 286-293

[10] Conley ME(2004)Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases J Clin Immunol 24 309-314

[1] Parvaneh N(2013)Primary immunodeficiencies: a rapidly evolving story J Allergy Clin Immunol 131 314-323

[2] Casanova JL(2015)Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015 J Clin Immunol 35 696-726

[3] Notarangelo LD(2010)Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G South Med J 103 856-863

[4] Conley ME(1973)Primary immunodeficiency diseases and cancer: the immunodeficiency-cancer registry Int J Cancer 12 333-347

[5] Picard C(2008)Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency—lessons learned from monogenic disorders in mice and men Curr Opin Immunol 20 646-654

[6] Al-Herz W(2011)Key aspects for successful immunoglobulin therapy of primary immunodeficiencies Clin Exp Immunol 164 16-19

[7] Bousfiha A(2010)Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology Clin Immunol 135 255-263

[8] Casanova JL(2009)Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies J Clin Immunol 29 137-144

[9] Chatila T(2006)Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia Vox Sang 90 286-293

[10] Conley ME(2004)Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases J Clin Immunol 24 309-314